Lexaria Bioscience Corp. (LEXX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Lexaria Bioscience Corp. (LEXX) is up 0.4% since the beginning of the year. At $1 per share, LEXX is trading 60.0% below its 52-week high of $2. Investors who bought $1,000 worth of LEXX shares 5 years ago would now be looking at an investment worth $90.

Lexaria Bioscience Corp. (LEXX) has returned 0.42% so far this year and -32.74% over the past 12 months. Over the last ten years, LEXX has returned -14.59% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since May 12, 2016, LEXX's average daily return is +0.14%, while the average monthly return is +2.48%. At this rate, an investment would double in approximately 2.4 years.

Historically, 38% of months were positive and 62% were negative. The best month was Feb 2024 with a return of +131.5%, while the worst month was May 2023 at -64.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.

On a daily basis, LEXX closed higher 44% of trading days. The best single day was Oct 17, 2016 with a return of +58.3%, while the worst single day was Jan 12, 2021 at -33.6%.

Lexaria Bioscience Corp. has an annualized alpha of 28.33%, beta of 0.75, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since May 13, 2016.

• This stock participated in 186.10% of S&P 500 Index downside but only 75.62% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LEXX ranks 30 for risk / return — below 30% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Lexaria Bioscience Corp. (LEXX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lexaria Bioscience Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lexaria Bioscience Corp. was 99.25%, occurring on Dec 26, 2025. The portfolio has not yet recovered.

The current Lexaria Bioscience Corp. drawdown is 99.12%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lexaria Bioscience Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lexaria Bioscience Corp. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.